Skip to contentB
Biogen Inc.
B
BIIBBiogen Inc. Source filing unavailable
Q4 2013 · —
Revenue$1.97B$1.97B+38.6% vs Q4 2012 Net Income$457.30M$457.30M+56.6% vs Q4 2012 EPS Diluted$1.92$1.92+56.1% vs Q4 2012 Gross Profit$1,707,300,000+33.0% Operating Incomederived$657,917,000+47.7% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
Operating Cash Flowderived$869,027,000+71.1% Free Cash Flowderived$790,355,000+80.1% Margins · derivedGross margin86.8%−3.7 pt vs Q4 2012
Operating margin33.5%+2.0 pt vs Q4 2012
Net margin23.3%+2.7 pt vs Q4 2012